What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
The scientist’s investigation covers issues in Bladder cancer, Surgery, Urology, Internal medicine and Cystectomy.
His studies in Bladder cancer integrate themes in fields like Urinary bladder, Carcinoma in situ, Pathology, Cystoscopy and Stage.
His Surgery study integrates concerns from other disciplines, such as Prostatectomy, Prostate cancer, Nomogram and Hazard ratio.
His studies deal with areas such as Cancer, Lymphovascular invasion, Transitional cell carcinoma, Lymph node and Carcinoma as well as Urology.
His research in Internal medicine intersects with topics in Gynecology and Oncology.
His Cystectomy research is multidisciplinary, relying on both Perioperative, Lymphadenectomy and Urothelial carcinoma.
His most cited work include:
- EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. (1390 citations)
- Epidemiology and risk factors of urothelial bladder cancer (1002 citations)
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013 (845 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Urology, Oncology, Bladder cancer and Cystectomy.
His work on Prostate cancer, Proportional hazards model, Nephrology and Disease as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines.
His study in Urology is interdisciplinary in nature, drawing from both Prostatectomy, Stage, Surgery, Carcinoma and Urothelial carcinoma.
His biological study spans a wide range of topics, including Upper tract, Meta-analysis, Chemotherapy and Survival rate.
Concomitant is closely connected to Carcinoma in situ in his research, which is encompassed under the umbrella topic of Bladder cancer.
His Cystectomy research incorporates elements of Urinary bladder, Lymphadenectomy, Lymphovascular invasion and Dissection.
He most often published in these fields:
- Internal medicine (62.54%)
- Urology (44.46%)
- Oncology (43.57%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (62.54%)
- Bladder cancer (39.39%)
- Oncology (43.57%)
In recent papers he was focusing on the following fields of study:
Shahrokh F. Shariat mostly deals with Internal medicine, Bladder cancer, Oncology, Urology and Prostate cancer.
In general Internal medicine study, his work on Meta-analysis, Hazard ratio, Epidemiology and Renal cell carcinoma often relates to the realm of In patient, thereby connecting several areas of interest.
Shahrokh F. Shariat studies Bladder cancer, focusing on Cystectomy in particular.
His research investigates the connection with Oncology and areas like Nivolumab which intersect with concerns in Ipilimumab.
The various areas that he examines in his Urology study include Stage, Proportional hazards model, Urothelial carcinoma and Lymph node.
His Prostate cancer research includes elements of Prostate and Radiation therapy.
Between 2019 and 2021, his most popular works were:
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† (36 citations)
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (28 citations)
- Risk Stratification Tools and Prognostic Models in Non–muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel (27 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
Shahrokh F. Shariat spends much of his time researching Internal medicine, Bladder cancer, Oncology, Cystectomy and Urology.
Shahrokh F. Shariat interconnects Clinical trial, Epidemiology, Carcinoma, Disease and Stage in the investigation of issues within Bladder cancer.
His Oncology research integrates issues from Pembrolizumab, Randomized controlled trial, Combination therapy and Chemotherapy.
His biological study spans a wide range of topics, including Odds ratio, Urinary bladder, Cumulative incidence, Perioperative and Radiation therapy.
His Urology research includes elements of Carcinoma in situ, Guideline, Upper tract, Urothelial carcinoma and Concomitant.
His research in Hazard ratio intersects with topics in Lower risk and Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
